The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
NCT07173127
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Uterine Fibroid
Interventions
DRUG:
Ryeqo treatment
Sponsor
University Hospital, Geneva